Stocks and Investing Stocks and Investing
Wed, May 10, 2023

David Amsellem Maintained (SUPN) at Buy with Increased Target to $46 on, May 10th, 2023


Published on 2024-10-28 03:39:08 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Increased Target from $45 to $46 on, May 10th, 2023.

David, nor any peers, have made any analyst calls on SUPN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources